Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Interleukin-based therapy for Metabolic disorders: c-Myc increases insulin sensitivity, restores mucosal immunity and decreases endotoxaemia via up regulation of Interleukin-22, 25/October/2014, 11.26, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Significance: This study suggests, for the first time, that c-Myc, by increasing the expression of IL-22, it may increase insulin sensitivity, restore gut immunity and decrease endotoxaemia. Together, this study suggests that pharmacological formulations encompassing “c-Myc activators” may be used to treat metabolic disorders, including T2DM and cardiac diseases.